The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery

J Bone Miner Metab. 2016 Nov;34(6):655-661. doi: 10.1007/s00774-015-0712-0. Epub 2015 Oct 5.

Abstract

Metabolic bone disease may appear as a complication of obesity surgery. Because an imbalance in the osteoprotegerin and receptor-activator of nuclear factor-κB ligand system may underlie osteoporosis, we aimed to study this system in humans in the metabolic bone disease occurring after obesity surgery. In this study we included sixty women with a mean age of 47 ± 10 years studied 7 ± 2 years after bariatric surgery. The variables studied were bone mineral density, β-isomer of C-terminal telopeptide of type I collagen cross-links (a bone resorption marker), the bone formation markers osteocalcin and N-terminal propeptide of procollagen 1, serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand. Serum osteoprotegerin inversely correlated with the bone remodeling markers osteocalcin, β-isomer of C-terminal telopeptide of type I collagen cross-links and N-terminal propeptide of procollagen 1. The osteoprotegerin and receptor-activator of nuclear factor-κB ligand ratio also correlated inversely with serum parathormone and osteocalcin. Bone mineral density at the lumbar spine was associated with age (β = -0.235, P = 0.046), percentage of weight loss (β = 0.421, P = 0.001) and osteoprotegerin and receptor-activator of nuclear factor-κB ligand ratio (β = 0.259, P = 0.029) in stepwise multivariate analysis (R 2 = 0.29, F = 7.49, P < 0.001). Bone mineral density at the hip site was associated only with percentage of weight loss (β = 0.464, P < 0.001) in stepwise multivariate regression (R 2 = 0.21, F = 15.1, P < 0.001). These data show that the osteoprotegerin and receptor-activator of nuclear factor-κB ligand system is associated with bone markers and bone mineral density at the lumbar spine after obesity surgery.

Keywords: Metabolic bone disease; Obesity surgery; Osteopenia; Osteoprotegerin; Receptor–activator of nuclear factor-κB ligand.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Bariatric Surgery / adverse effects*
  • Biomarkers / blood
  • Bone Density*
  • Bone Diseases, Metabolic* / blood
  • Bone Diseases, Metabolic* / etiology
  • Female
  • Humans
  • Middle Aged
  • Obesity* / blood
  • Obesity* / surgery
  • Osteocalcin / blood
  • Osteoprotegerin / blood*
  • Parathyroid Hormone / blood
  • Pelvic Bones / metabolism
  • Postoperative Complications / blood*
  • RANK Ligand / blood*
  • Spine / metabolism

Substances

  • Biomarkers
  • Osteoprotegerin
  • Parathyroid Hormone
  • RANK Ligand
  • TNFRSF11B protein, human
  • TNFSF11 protein, human
  • Osteocalcin